ArticlePloS one2013
Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Highly sensitive live-cell imaging-based cytotoxicity assay enables functional validation of rare epitope-specific CTLs.Frontiers in immunology · 2025Article
- A luminescence-based method to assess antigen presentation and antigen-specific T cell responses forFrontiers in immunology · 2023Article
- Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure.Frontiers in immunology · 2023Article
- Characterization of the conserved regions of E1A protein from human adenovirus for reinforcement of cytotoxic T lymphocytes responses to the all genogroups causes ocular manifestation through an in silico approach.Iranian journal of microbiology · 2022Article
- Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.Frontiers in immunology · 2020Review
- Intestinal HAdV Infection: Tissue Specificity, Persistence, and Implications for Antiviral Therapy.Viruses · 2019Review
- Article
- Tracking T-cell immune reconstitution after TCRαβ/CD19-depleted hematopoietic cells transplantation in children.Leukemia · 2017Article
- Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection.Journal of translational medicine · 2016Article
- Human CD8(+) T Cells Target Multiple Epitopes in Respiratory Syncytial Virus Polymerase.Viral immunology · 2016Article
- A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapy.Scientific reports · 2016Article
- New drug on the horizon for treating adenovirus.Expert opinion on pharmacotherapy · 2015Article
- The role of CD4(+) T cells in BKV-specific T cell immunity.Medical microbiology and immunology · 2014Article
- Adenovirus infections in immunocompetent and immunocompromised patients.Clinical microbiology reviews · 2014Review
- Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.Bone marrow transplantation · 2014Article
- Article
- Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adenoviral infections are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients. Adoptive transfer of donor-derived human adenovirus (HAdV)-specific T-cells represents a promising treatment option. However, the difficulty in identifying and selecting rare HAdV-specific T-cells, and the short time span between patients at high risk for invasive infection and viremia are major limitations. We therefore developed an IL-15-driven 6 to 12 day short-term protocol for in vitro detection of HAdV-specific T cells, as revealed by known MHC class I multimers and a newly identified adenoviral CD8 T-cell epitope derived from the E1A protein for the frequent HLA-type A*02∶01 and IFN-γ. Using this novel and improved diagnostic approach we observed a correlation between adenoviral load and reconstitution of CD8(+) and CD4(+) HAdV-specific T-cells including central memory cells in HSCT-patients. Adaption of the 12-day protocol to good manufacturing practice conditions resulted in a 2.6-log (mean) expansion of HAdV-specific T-cells displaying high cytolytic activity (4-fold) compared to controls and low or absent alloreactivity. Similar protocols successfully identified and rapidly expanded CMV-, EBV-, and BKV-specific T-cells. Our approach provides a powerful clinical-grade convertible tool for rapid and cost-effective detection and enrichment of multiple virus-specific T-cells that may facilitate broad clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.